Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (3) Autor Ribeiro-Silva,A. (3) Garcia,S.B. (2) Andrade,J.M. (1) Aprilli,F. (1) Buzatto,I.P.C. (1) Carrara,H.H.A. (1) Cunha,F.Q. (1) Escalante,R.D. (1) Ramalho,L.N.Z. (1) Silveira,W.A. (1) Tiezzi,D.G. (1) Vespúcio,M.V.O. (1) Zucoloto,S. (1) de Oliveira,Ê.C. (1) Mais... Palavra-chave Breast (1) Carcinoma (1) Colon carcinogenesis (1) Dimethylhydrazine (1) EBNA-1 (1) Metallothioneins (1) Neoadjuvant chemotherapy (1) Nimesulide (1) P53 (1) P63 (1) Pathologic complete response (1) Predictive factors of response (1) Prognosis (1) Trastuzumab (1) Trypanosoma cruzi (1) Tumorigenesis (1) Mais... Tipo do documento Info:eu-repo/semantics/article (3) Ano 2017 (1) 2006 (1) 2004 (1) País Brazil (3) Idioma Inglês (3)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 3 Primeira ... 1 ... Última Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies? BJMBR Ribeiro-Silva,A.; Ramalho,L.N.Z.; Garcia,S.B.; Zucoloto,S.. Several investigators have identified Epstein-Barr virus (EBV) particles in breast carcinomas, a fact that supports a role for EBV in mammary tumorigenesis. The possible mechanism involved in this process is not clear. The present study was carried out in an attempt to determine whether there is a relationship between latent infection with EBV and p53 and p63 expression in breast carcinomas. Immunohistochemistry developed with 3.3-diaminobenzidine tetrahydrochloride was performed in 85 formalin-fixed paraffin-embedded breast carcinomas using anti-EBV EBNA-1, anti-p63, anti-p53, anti-estrogen receptor (ER) and anti-progesterone receptor (PR) antibodies. The cases were selected to represent each of the various histologic types: intraductal carcinoma (N =... Tipo: Info:eu-repo/semantics/article Palavras-chave: EBNA-1; P63; P53; Breast; Carcinoma; Tumorigenesis. Ano: 2004 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004000100013 Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors BJMBR Buzatto,I.P.C.; Ribeiro-Silva,A.; Andrade,J.M.; Carrara,H.H.A.; Silveira,W.A.; Tiezzi,D.G.. The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 to 2013 and to determine possible predictive and prognostic factors. Immunohistochemistry for hormone receptors and Ki-67 was carried out. Clinical and pathological features were analyzed as predictive factors of response to therapy. For survival analysis, we used Kaplan-Meier curves to estimate 5-year survival rates and the log-rank test to compare the curves. The addition of trastuzumab to neoadjuvant chemotherapy significantly improved pCR rate from 4.8 to 46.8%, regardless of the number of preoperative trastuzumab... Tipo: Info:eu-repo/semantics/article Palavras-chave: Neoadjuvant chemotherapy; Trastuzumab; Pathologic complete response; Predictive factors of response; Prognosis. Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000200702 Trypanosoma cruzi infection and/or administration of the nonsteroidal anti-inflammatory nimesulide increase the number of colonic crypts overexpressing metallothioneins in rat colon carcinogenesis BJMBR Escalante,R.D.; de Oliveira,Ê.C.; Cunha,F.Q.; Vespúcio,M.V.O.; Ribeiro-Silva,A.; Aprilli,F.; Garcia,S.B.. Trypanosoma cruzi infection and nonsteroidal anti-inflammatory drugs inhibit colorectal carcinogenesis by mechanisms not completely known and metallothionein proteins (MTs) may be involved in this process. Sixty-six male Wistar rats weighing 90 to 120 g were randomly divided into seven groups (GI to GVII). GI, GII and GIII animals were subcutaneously infected with 200,000 trypomastigote forms of the Y strain of T. cruzi. After 8 weeks, GI, GII, GIV, and GVI were injected with one weekly subcutaneous dose of 12 mg/kg dimethylhydrazine for 4 weeks. In sequence, GI, GIV and GV were treated with nimesulide (10 mg/kg per dose, five times per week for 8 weeks). Groups I, III, IV, and VI had 12 animals, and each of the other groups had 6 animals. All the animals... Tipo: Info:eu-repo/semantics/article Palavras-chave: Trypanosoma cruzi; Nimesulide; Dimethylhydrazine; Metallothioneins; Colon carcinogenesis. Ano: 2006 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000700007 Registros recuperados: 3 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco